Diagnosing SARS-CoV-2 associated Guillain-Barre syndrome requires cerebro-spinal-fluid studies

We read with interest the article by Papri et al. about a 50yo male who was diagnosed with Guillain Barre syndrome (GBS) subtype acute inflammatory demyelinating polyneuropathy (AIDP) according to the National Institute of Neurological Disorders and Stroke (NINDS) criteria upon the clinical presentation and nerve conduction studies (NCSs) 6  weeks after onset of an infection with SARS-CoV-2 (Papri et al., 2021). The patient received immunoglobulines and recovered slowly but almost completely over a period of 6 months (Papri et al., 2021).
Source: Journal of Neuroimmunology - Category: Allergy & Immunology Authors: Tags: Letter to the Editor Source Type: research